Oabf 25mg Tablet contains Mirabegron 25mg, a selective β3-adrenoceptor agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urinary urgency, frequency, and urge incontinence. Mirabegron works by relaxing the detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle, thereby increasing bladder capacity without compromising voiding function. This mechanism helps reduce the frequency of micturition and episodes of urgency incontinence, improving patient quality of life. Oabf 25mg is typically administered orally once daily, with or without food, and dosage adjustments may be necessary in patients with renal or hepatic impairment. The safety and efficacy of Mirabegron have been established in multiple clinical trials, demonstrating a favorable tolerability profile with common adverse effects including hypertension, headache, and nasopharyngitis. Caution is advised in patients with severe uncontrolled hypertension or bladder outlet obstruction. Oabf 25mg should be used under medical supervision, with periodic monitoring of blood pressure and renal function recommended during treatment. This medication offers an effective alternative to antimuscarinic agents, particularly in patients who experience intolerable anticholinergic side effects.